Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment

Expert Opinion on Investigational Drugs

Volumn 21, Issue 12, 2012, Pages 1789-1800

  Engohang Ndong, Jean ^a,b  

^a KENT STATE UNIVERSITY   (United States)

^b UNIVERSITÉ DES SCIENCES ET TECHNIQUES DE MASUKU   (Gabon)

Author keywords

Anti tuberculosis drugs; Extensively drug resistant; Multidrug resistant; Mycobacterium tuberculosis; Phase II clinical trials; Preclinical phase

Indexed keywords

7 (7 AMINO 7 METHYL 5 AZASPIRO[2.4]HEPTAN 5 YL) 6 FLUORO 1 (2 FLUOROCYCLOPROPYL) 1,4 DIHYDRO 8 METHOXY 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMIKACIN; AMINOSALICYLIC ACID; BDM 31343; BEDAQUILINE; BTZ 043; CAPREOMYCIN; CIPROFLOXACIN; CPZEN 45; DC 159 A; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; MYCOLIC ACID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITROIMIDAZOLE DERIVATIVE; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PROTIONAMIDE; PYRAZINAMIDE; RBX 8700; RIFAMPICIN; SQ 641; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANXIETY; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GYNECOMASTIA; HALLUCINATION; HUMAN; HYPERSALIVATION; HYPERTHYROIDISM; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; OPTIC NEURITIS; PHASE 2 CLINICAL TRIAL (TOPIC); QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TUBERCULOSIS; VOMITING;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84868704828     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.724397     Document Type: Review

References (72)

1. World Health Organization. Global tuberculosis control. WHO 2011 report. Press Release (2011): 2011
2. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB). global report on surveillance and response. Press Release (2010). 2010
3. Schatz A, Waksman SA. Effect of Streptomycin and Other Antibiotic Substances upon Mycobacterium tuberculosis and Related Organisms. Proc Soc Experiment Biol Med 1944;57(2):244-8
4. Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 1946;1(6384):15
5. Nitti V. Antituberculosis activity of rifampin. Report of studies performed and in progress (1966-1971). Chest 1972;61(6):589-98
6. World Health Organization. Treatment of Tuberculosis. Guidelines for National Programmes. Press Release (2003). 2003
7. Alangaden GJ, Kreiswirth BN, Aouad A, et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42(5):1295-7
8. Kruuner A, Jureen P, Levina K, et al. Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47(9):2971-3
9. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49(8):3192-7
10. Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs 2010;24(8):655-67
11. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001;61(1):9-18
12. Bryskier A, Lowther J. Fluoroquinolones and tuberculosis. Expert Opin Investig Drugs 2002;11(2):233-58
13. Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008;31(4):904-5
14. Aubry A, Veziris N, Cambau E, et al. Novel gyrase mutations in quinolone-resistant and-hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006;50(1):104-12
15. Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38(4):773-80
16. Xu C, Kreiswirth BN, Sreevatsan S, et al. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 1996;174(5):1127-30
17. Yamazaki H. In vitro experiments on the tuberculo-bacteriostatic activity of o-aminophenol, p-aminosalicylic acid, streptomycin and tibione in the presence of p-aminobenzoic acid. Jpn Med J (Natl Inst Health Jpn) 1950;3(5):299-307
18. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006;10(8):829-37
19. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38(3):516-28
20. Quemard A, Laneelle G, Lacave C. Mycolic acid synthesis: a target for ethionamide in mycobacteria? Antimicrob Agents Chemother 1992;36(6):1316-21
21. Protopopova M, Hanrahan C, Nikonenko B, et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005;56(5):968-74
22. Tahlan K, Wilson R, Kastrinsky DB, et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012;56(4):1797-809
23. Chen P, Gearhart J, Protopopova M, et al. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006;58(2):332-7
24. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010;54(7):2840-6
25. Jia L, Coward L, Gorman GS, et al. Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J Pharmacol Exp Ther 2005;315(2):905-11
26. SQ109. 2012. Avilable from http://www.newtbdrugs.org/project.php?id=144
27. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307(5707):223-7
28. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51(3):1011-15
29. Ibrahim M, Truffot-Pernot C, Andries K, et al. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009;180(6):553-7
30. Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006;50(11):3543-7
31. Veziris N, Ibrahim M, Lounis N, et al. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 2011;6(3):e17556
32. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52(8):2831-5
33. Diacon AH, Donald PR, Pym A, et al. Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance. Antimicrob Agents Chemother 2012;56(6):3271-6
34. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405(6789):962-6
35. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2009;2(3):215-18
36. Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008;322(5906):1392-5
37. Ahmad Z, Peloquin CA, Singh RP, et al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 2011;55(1):239-45
38. Nuermberger E, Rosenthal I, Tyagi S, et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2006;50(8):2621-5
39. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52(4):1522-4
40. Diacon AH, Dawson R, du Bois J, et al. Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824. Antimicrob Agents Chemother 2012;56(6):3027-31
41. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3(11):e466
42. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366(23):2151-60
43. Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis. 2012.Available from: http://www. newtbdrugs.org/project.php?id=136
44. Alcala L, Ruiz-Serrano MJ, Perez-Fernandez Turegano C, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003;47(1):416-17
45. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997;41(10):2132-6
46. Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009;53(4):1314-19
47. Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178(11):1180-5
48. Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008;134(1):187-92
49. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases. J Infect 2006;52(2):92-6
50. Singla R, Caminero JA, Jaiswal A, et al. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur Respir J 2012;39(4):956-62
51. Alffenaar JW, van der Laan T, Simons S, et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 2011;55(3):1287-9
52. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012;56(6):3114-20
53. Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. J Bras Pneumol 2010; 36(5):641-56
54. Baulard AR, Betts JC, Engohang-Ndong J, et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem 2000; 275(36):28326-31
55. Engohang-Ndong J, Baillat D, Aumercier M, et al. EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Mol Microbiol 2004;51(1):175-88
56. Schumacher MA, Miller MC, Grkovic S, et al. Structural mechanisms of QacR induction and multidrug recognition. Science 2001;294(5549):2158-63
57. Frenois F, Engohang-Ndong J, Locht C, et al. Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. Mol Cell 2004;16(2):301-7
58. Willand N, Dirie B, Carette X, et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med 2009;15(5):537-44
59. Flipo M, Desroses M, Lecat-Guillet N, et al. Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. J Med Chem 2011;54(8):2994-3010
60. Flipo M, Desroses M, Lecat-Guillet N, et al. Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. J Med Chem 2012;55(1):68-83
61. SQ609. 2011. Avilable from http://www.sequella.com/docs/Sequella-1sheet- SQ609-v1.pdf
62. Bogatcheva E, Dubuisson T, Protopopova M, et al. Chemical modification of capuramycins to enhance antibacterial activity. J Antimicrob Chemother 2011;66(3):578-87
63. Muramatsu Y, Muramatsu A, Ohnuki T, et al. Studies on novel bacterial translocase I inhibitors, A-500359s. I. Taxonomy, fermentation, isolation, physico-chemical properties and structure elucidation of A-500359 A, C, D and G. J Antibiot (Tokyo) 2003;56(3):243-52
64. Reddy VM, Einck L, Nacy CA. In vitro antimycobacterial activities of capuramycin analogues. Antimicrob Agents Chemother 2008;52(2):719-21
65. Koga T, Fukuoka T, Doi N, et al. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J Antimicrob Chemother 2004;54(4):755-60
66. Nikonenko BV, Reddy VM, Protopopova M, et al. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob Agents Chemother 2009;53(7):3138-9
67. CPZEN-45. 2011. Avilable from http://www.newtbdrugs.org/project.php?id=92
68. Sood R, Rao M, Singhal S, Rattan A. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. Int J Antimicrob Agents 2005;25(6):464-8
69. Ahmad Z, Minkowski A, Peloquin CA, et al. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob Agents Chemother 2011;55(4):1781-3
70. Sekiguchi J, Disratthakit A, Maeda S, Doi N. Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone. Antimicrob Agents Chemother 2011;55(8):3958-60
71. Makarov V, Manina G, Mikusova K, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009;324(5928):801-4
72. Manina G, Bellinzoni M, Pasca MR, et al. Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance. Mol Microbiol 2010;77(5):1172-85